Profile | Research

Wormley Jr., Floyd, Layton

Assistant Professor






Tulane University, New Orleans, LA



Cell and Molecular Biology

LSU Health Sciences Center, New Orleans, LA




LSU Health Sciences Center, New Orleans, LA




Duke University Medical Center, Durham, NC



Infectious Diseases


Positions and Honors


1995-2001       Graduate Research Associate, Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA
1998                Instructor, Department of Biology, Xavier University, New Orleans, LA
2002-2005       Postdoctoral Research Associate, Department of Medicine/Division of Infectious Diseases, Duke University Medical Center
2005-Present  Assistant Professor, Department of Biology, University of Texas at San Antonio, San Antonio, TX

Honors and Fellowships

1997-2000                   NIH Supplement for Underrepresented Minorities Grant

2000                Who’s Who Among Students In American Universities & Colleges
2002                Chancellor’s Superior Graduate Student Award, LSU Health Sciences Center, New Orleans, LA
2002-2005       NIH Loan Repayment Program for Clinical Research
2002-2005       Postdoctoral Research Fellowship, AIDS Interdisciplinary Institutional Research Training Grant, Department of Medicine, Division of Infectious Diseases, Duke University Medical Center
2005                Oral Presentation – Cryptococcus & Cryptococcosis Tri-annual Meeting

Professional Societies

1998-present   Member, American Society for Microbiology
2005-present   Member, Medical Mycological Society of the Americas
Selected peer-reviewed publications (in chronological order).

  1. Leigh, J.E., C. Steele, F.L. Wormley Jr., W. Luo, R. Clark, W. Gallaher, and P.L. Fidel Jr., (1998) Th1/Th2 cytokine expression in saliva of HIV+ and HIV- individuals: A pilot study in HIV+ individuals with oropharyngeal candidiasis. J AIDS and Human Retrovirology. 19(4): 373-380.
  2. Fidel, P.L. Jr., W. Luo, C. Steele, J. Chabain, and F.L. Wormley Jr., (1999) Analyses of vaginal cell populations during experimental C. albicans vaginitis.  Infection and Immunity. 67(6): 3135-3140.
  3. F.L. Wormley Jr., M. Scott, W. Luo, M. Baker, J. Chabain, and PL. Fidel, Jr., (2000) Evidence for a unique CD4 protein on murine vaginal CD4+ T cells.  Immunology. 100: 300-308.
  4. K.A. Kelly, H.L. Gray, J.C. Walker, R.G. Rank, F.L. Wormley Jr., and P.L. Fidel Jr., (2001) Chlamydia trachomatis infection does not enhance local cellular immunity against concurrent Candida vaginal infection.  Infection and Immunity. 69(5): 3451-3454.
  5. F.L. Wormley Jr., J. Chaiban, and P.L. Fidel Jr., (2001) Cell adhesion molecule and lymphocyte activation marker expression during experimental vaginal candidiasis.  Infection and Immunity. 69(8):  5072-5079.
  6. P.L. Fidel Jr., F.L. Wormley Jr., J. Chaiban, R.R. Chesson, and V. Lounev, (2001) Analysis of the CD4 protein on human vaginal T lymphocytes.  American Journal of Reproductive Immunology. 45: 200-204.
  7. F.L. Wormley Jr., C. Steele, K. Wozniak, K. Fujihashi, J.R. McGhee, and P.L. Fidel Jr., (2001) Resistance of TCR d chain deficient mice to experimental Candida vaginitis.  Infection and Immunity. 69(11): 7162-7164.
  8. J.E. Leigh, C. Steele, F.L. Wormley Jr., and P.L. Fidel Jr., (2002) Salivary cytokine profiles in the immunocompetent individual with Candida associated denture stomatitis.  Oral Microbiology and Immunology.  17(5): 311-314.
  9. L. Cardenas-Freytag, C. Steele, F.L. Wormley Jr., E. Cheng, J.D. Clements and P.L. Fidel Jr., (2002) Partial protection against experimental vaginal candidiasis after mucosal vaccination with heat-killed Candida albicans and the mucosal adjuvant LT(R192G). Medical Mycology. 40(3): 291-299.
  10. K.L. Wozniak, F.L. Wormley Jr., P.L. Fidel Jr., (2002) Candida-specific antibodies during experimental vaginal candidiasis in mice.  Infection and Immunity.  70(10): 5790-5799.
  11. F.L. Wormley Jr., J. Cutright, and P.L. Fidel Jr., (2003) Multiple experimental designs to evaluate the role of T-cell-mediated immunity against experimental vaginal Candida albicans infection.  Med Mycol. 41(5): 401-9.
  12. J.R. Blankenship, F.L. Wormley Jr., M.K. Boyce, W.A. Schell, S.G. Filler, J.R. Perfect, J. Heitman, (2003) Calcineurin is essential for Candida albicans survival in serum and virulence. Eukaryotic Cell.  2(3): 422-30.
  13. C. Onyewu, F. L. Wormley, Jr., J. R. Perfect, and J. Heitman, (2004) Calcineurin target Crz1 functions in azole-tolerance but is not required for virulence of Candida albicans.  Infection and Immunity 72(12):  7330-7333.
  14. F.L. Wormley, Jr., G.M. Cox, and J. R. Perfect. (2005) Evaluation of host immune responses to pulmonary cryptococcosis using a temperature-sensitive C. neoformans Calcineurin A mutant strain. Microbial Pathogenesis 38:  113-123.
  15. F.L. Wormley Jr. and J.R. Perfect. (2005) Immunology of infection owing to Cryptococcus neoformans, in Antifungal Agents: Methods and Protocols (E.J. Ernst and P.D. Rogers, eds.), Humana, Totowa, NJ.
  16. F.L. Wormley, Jr., G. Heinrich, J.L. Miller, J. R. Perfect, and G.M. Cox. (2005) Identification and characterization of an SKN7 homologue in Cryptococcus neoformans. Infection and Immunity 73(8).
  17. F.L. Wormley, Jr., J. R. Perfect, C. Steele, and G.M. Cox. (2006) Protection against cryptococcosis using a murine Interferon-gamma-producing Cryptococcus neoformans strain. Infection and Immunity. (manuscript in revision).
Research Support

T32 AI007392-15         02/28/2002 – 08/01/2005
Agency:  NIH
Institutional Training Grant, Duke University Medical Center
Program in microbial pathogenesis of Cryptococcus neoformans
RO1AI071752-01A2    04/01/2007 – 03/30/2012
Agency:  NIH (Priority Score:110; Percentile: 3.5)
Project Title:  “Protective Host Immunity Against Pulmonary Cryptococcosis”
The long term goal of this project is to describe protective immunity against C. neoformans infections.


Health Science Center seal

Links provided from Health Science Center pages to other web sites do not constitute or imply an endorsement of those sites, their content, or products and services associated with those sites.
Best viewed at 1024x768 resolution.